Welcome to Labeled Immunoassays and Clinical Medicine website!
Orignal Article

The Role of Peritoneal Dialysis to NK Cell and T Cell Subsets forEndstage Renal Disease Patients

  • SUN Jianjie ,
  • CHEN Chao ,
  • SHI Feng ,
  • DING Junli ,
  • WANG Li ,
  • YAO Suhua ,
  • MA Liping ,
  • YIN Guangyue
Expand
  • Department of Nephrology,Petroleum Affiliated Hospital of Hebei Medical University, Langfang 065000, China

Received date: 2012-10-24

  Online published: 2013-08-20

Abstract

bjective To detect whether peritoneal dialysis can change the cellular immune function in patients with endstage renal disease.Methods The expression of CD3+, CD4+ and the rate of CD4+ / CD8+ were determined by the flow cytometric method. Results Compared with the patients before peritoneal dialysis, the expression of CD3+, CD4+ and the rate of CD4+ / CD8+ were significantly increased in the patients with peritoneal dialysis after 6 months, 12 months respectively and more higher than that of in the patients after 12 months. CD8+ had no significantly changes after peritoneal dialysis. NK cells were significantly decreased in the patients with peritoneal dialysis after 6 months, 12 months respectively. Conclusion The peritoneal dialysis can improve cellular immune function in ESRD patients.

Cite this article

SUN Jianjie , CHEN Chao , SHI Feng , DING Junli , WANG Li , YAO Suhua , MA Liping , YIN Guangyue . The Role of Peritoneal Dialysis to NK Cell and T Cell Subsets forEndstage Renal Disease Patients[J]. Labeled Immunoassays and Clinical Medicine, 2013 , 20(2) : 76 -78 . DOI: 10.11748/bjmy.issn.1006

References

[1] 毕增祺,郑法雷,李学旺. 慢性肾功能衰竭[M]. 北京: 中国协和医科大学出版社, 2003: 213214.
[2] 王海燕. 肾脏病学[M]. 第2版.北京: 人民卫生出版社, 2008: 20842085.
[3] Koc Y,Unsal A,Ahbap E, et al. Clinical outcome of diabetic peritoneal dialysis patients and evaluation of factors affccting mortality: a single centre’s experience from Turkey [J]. J Ren Care,2011,37(2):94100.
[4] Sarnak M, Jaber B. Mortality caused by sepsis in patients with endstage renal disease compared with the normal population[J].Kidney Int,2000,54(4):17581764.
[5] 伍凌云,张训,侯凡凡.尿毒症毒素在维持性血透患者细胞免疫缺陷中的作用[J].中华肾脏病杂志,1995,11(增刊):35.
[6] Griveas I, Visvardis G, Fleva A, et al. Lymphocytes subsets in the course of continuous ambulatory peritoneal dialysis (CAPD) [J]. Ren Fail, 2004,26(6): 641646.
[7] Griveas I, Visvardis G, Fleva A, et al. Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis[J]. Ren Fail,2005,27: 279282.
[8] Chansritrakul S, EiamOng S, Kansanabuch T, et al. Continuous ambulatory peritoneal dialysis improves both the number and memory function of CD4 T cells in uremic patients[J]. J Med Assoc hai,2004,87(4):389394.
[9] Caligiuri M A. Human natural killer cells [J]. Blood, 2008,112(8):461469.
[10] Stenvinkel P,Wanner C,Metzger T,et al. Inflammation and outcome in endstage renal failure :does female gender constitute a survival advantage?[J]. Kidney Int,2002,62 (5) :17911798.
[11] Kaysen G A. The microinflammatory state in uremia: causes and potential consequences [J] . J Am Soc Nephrol,2001,12(7) :15491557.
Outlines

/